Literature DB >> 9332335

Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen.

N Schaap1, A Schattenberg, B Bär, F Preijers, A Geurts van Kessel, R van der Maazen, T de Boo, T de Witte.   

Abstract

One hundred and eighty-one consecutive patients with standard-risk leukaemia were transplanted with HLA-identical sibling grafts depleted of lymphocytes using counter-flow centrifugation. In 116 patients, standard conditioning was intensified by the addition of anthracyclines. Multivariate analysis revealed significantly more acute GVHD > or = grade 2 and a trend towards more chronic GVHD in patients conditioned with the addition of anthracyclines. For all patients the risk for chronic GVHD, but not for acute GVHD increased with a higher number of T cells in the graft. The projected 5-year probability of relapse was significantly lower in the group of patients conditioned with anthracyclines; 26% versus 52% (P = 0.015). In multivariate analysis the addition of anthracyclines to the conditioning regimen was the only significant factor contributing to a lower probability of relapse. The projected 5-year probability of leukaemia-free survival [LFS] in the patients conditioned with and without the addition of anthracyclines was 56% and 36%, respectively (P = 0.004). In multivariate analysis the addition of anthracyclines to the conditioning regimen correlated significantly with a lower number of mixed chimaeras in patients at 6 and 12 months after BMT. Mixed chimaerism at 6 months after transplantation did not significantly correlate with a higher incidence of relapse in further follow-up. In contrast, mixed chimaerism at 12 months after BMT was significantly associated with higher relapse rate. We conclude that the addition of anthracyclines to the conditioning regimen improves outcome of BMT using T-cell-depleted grafts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9332335     DOI: 10.1046/j.1365-2141.1997.d01-3499.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients.

Authors:  N M A Blijlevens; J P Donnelly; A H J Naber; A V M B Schattenberg; B E DePauw
Journal:  Support Care Cancer       Date:  2005-03-15       Impact factor: 3.603

2.  Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Willemijn Hobo; Kelly Broen; Walter J F M van der Velden; Annelies Greupink-Draaisma; Niken Adisty; Yannick Wouters; Michel Kester; Hanny Fredrix; Joop H Jansen; Bert van der Reijden; J H Frederik Falkenburg; Theo de Witte; Frank Preijers; Ton Schattenberg; Ton Feuth; Nicole M Blijlevens; Nicolaas Schaap; Harry Dolstra
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-27       Impact factor: 5.742

3.  Measuring mucosal damage induced by cytotoxic therapy.

Authors:  N M A Blijlevens; B van't Land; J P Donnelly; L M'Rabet; B E de Pauw
Journal:  Support Care Cancer       Date:  2004-01-30       Impact factor: 3.603

4.  Evaluation of Apoptosis in Multipotent Hematopoietic Cells of Bone Marrow by Anthracycline Antibiotics.

Authors:  Asieh Aramvash; Azra Rabbani Chadegani; Safa Lotfi
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

5.  High incidence of graft failure in children receiving CD34+ augmented elutriated allografts for nonmalignant diseases.

Authors:  C H McDonough; D A Jacobsohn; G B Vogelsang; S J Noga; A R Chen
Journal:  Bone Marrow Transplant       Date:  2003-06       Impact factor: 5.483

6.  Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms.

Authors:  Leo Ruhnke; Friedrich Stölzel; Uta Oelschlägel; Malte von Bonin; Katja Sockel; Jan Moritz Middeke; Christoph Röllig; Korinna Jöhrens; Johannes Schetelig; Christian Thiede; Martin Bornhäuser
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.